Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 16/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30754092 | 0.88 | PTGER4 (0.42) | PTGER4PTGER2 | |
| SCHEMBL30754103 | 0.85 | PTGER4 (0.47) | PTGER4PTGER2NSD2 | |
| SCHEMBL30754111 | 0.81 | PTGER4 (0.50) | PTGER4PTGER2 | |
| SCHEMBL31490043 | 0.80 | PTGER2 (0.52) | PTGER4PTGER2 | |
| SCHEMBL30754093 | 0.79 | PTGER4 (0.45) | PTGER4PTGER2 | |
| SCHEMBL30754094 | 0.79 | PTGER4 (0.45) | PTGER4PTGER2 | |
| SCHEMBL30754114 | 0.79 | PTGER4 (0.45) | PTGER4PTGER2 | |
| SCHEMBL30754088 | 0.76 | PTGER4 (0.58) | PTGER4PTGER2 | |
| SCHEMBL30754080 | 0.76 | PTGER4 (0.58) | PTGER4PTGER2 | |
| SCHEMBL30754084 | 0.74 | PTGER4 (0.47) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565565-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | Nxera Pharma UK Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| CN-119654310-A | 1, 2-Substituted 3-oxo-pyrazolidine derivatives as prostaglandin E2 receptor 4 (EP 4) agonists for the treatment of gastrointestinal and pulmonary diseases | 奈克斯拉制药英国有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024028601-A1 | 1,2-SUBSTITUTED 3-OXOPYRAZOLIDINE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |